Melbourne blood-clotting case 'likely' linked to AstraZeneca vaccine, Deputy CMO says


Australian regulator the Therapeutic Goods Administration (TGA) has said previously the AstraZeneca vaccine was not tied to an increase in overall risk of blood clots, however.

The World Health Organisation and the EU's health watchdog have both deemed the AstraZeneca vaccine safe after fears were raised of the jab having serious side effects.

On Tuesday, an independent vaccine expert panel in Germany said AstraZeneca shots should not routinely be given to people under 60 because of a rise in reported cases of unusual blood clots in the days after vaccination.

Australia has been highly successful in curbing the virus with snap lockdowns, border closures and swift tracking, reporting just under 29,300 infections and 909 deaths.

"The government is also committed to ensuring that the Malaysian adult population achieves herd immunity, in line with the target of the National Covid-19 Immunisation Programme", he said.

The U.K. reported 25 new cases of rare blood clots possibly linked to AstraZeneca Plc's Covid-19 vaccine as the Netherlands became the latest country to restrict use of the shot.

The AstraZeneca and Pfizer vaccines have shown "very high levels of protection" against Covid-19, the agency said, adding that "all vaccines and medicines have some side effects".

Seven people in the United Kingdom have died from unusual blood clots after receiving the AstraZeneca Covid-19 jab.

"My general feeling is that given the contractual relationships that we have with a number of companies, that we have enough vaccine to fulfill all of our needs without invoking AstraZeneca", he said.

Lareb said the events had occurred 7 to 10 days after vaccination. The vaccine received conditional approval on March 2.

Of these, it said it had received 22 reports of cerebral venous sinus thrombosis and eight reports of other thrombosis events with low platelets.

Some countries have restricted use of the AstraZeneca vaccine while others have resumed inoculations, as investigations into reports of rare, and sometimes severe, blood clots continue.

Emer Cooke, executive director of the European Medicines Agency, said Wednesday that her Amsterdam-based agency continues to study reports of new cases as they come in and will provide a further assessment next week.



Other news